Key result
SGLT2 inhibitors consistently reduce HF hospitalizations and cardiovascular events across all LVEF phenotypes.
Why the study?
This review summarizes the mechanisms, clinical evidence, safety profile, and guideline recommendations for SGLT-2 inhibitors in heart failure across the ejection fraction spectrum.
Do SGLT-2 inhibitors reduce heart failure hospitalization and cardiovascular outcomes in adult patients with heart failure across the ejection fraction spectrum?
Do SGLT-2 inhibitors reduce heart failure hospitalization and cardiovascular outcomes in adult patients with heart failure across the ejection fraction spectrum?
This narrative review summarizes evidence from landmark trials confirming that SGLT-2 inhibitors are foundational therapy across the entire spectrum of heart failure ejection fraction, reducing hospitalizations and providing cardiorenal benefits irrespective of diabetes status.
Answers are grounded in this paper and cite their sources.
Reinforces SGLT-2 inhibitors as foundational HF therapy across EF spectra; confirms RCT benefits independent of diabetes.
Objective: To review the role of SGLT-2 inhibitors in heart failure across the spectrum of ejection fraction, including mechanisms, clinical evidence, safety profile, and guideline recommendations. Methods: A narrative review was conducted using PubMed, MEDLINE, and Google Scholar (2015–2025), along with major cardiology guidelines. Results: Major randomized controlled trials including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, and EMPULSE demonstrate significant reductions in heart failure hospitalization and cardiovascular outcomes across all phenotypes. Benefits are independent of diabetes status and include renal protection and improved quality of life. Conclusion: SGLT-2 inhibitors are now established as foundational therapy in heart failure management.
No takes yet. Share an insight, caveat, or question.
HUSSAIN et al. (2026) conducted a review in Heart failure. SGLT-2 inhibitors (dapagliflozin, empagliflozin, sotagliflozin) vs. Placebo was evaluated on Heart failure hospitalization and composite cardiovascular outcomes. SGLT-2 inhibitors consistently reduce heart failure hospitalizations and composite cardiovascular outcomes across all ejection fraction phenotypes, independent of diabetes status.
Synapse has enriched 10 related papers. Consider them for comparative context: